logo

Celldex Therapeutics Inc. (CLDX)



Trade CLDX now with
  Date
  Headline
8/8/2018 4:03:58 PM Celldex Therapeutics Q2 Loss/share $0.11 Vs. Loss $0.23 Year Ago
5/10/2018 8:04:17 AM Celldex Therapeutics Q1 Loss Per Share $0.84 Vs Loss $0.28 Last Year
4/16/2018 7:01:36 AM Celldex Says METRIC Study In Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint
3/7/2018 4:03:13 PM Celldex Therapeutics Q4 Loss/share $0.03 Vs. Loss $0.30 Year Ago
11/30/2017 8:02:34 AM Celldex Therapeutics Opens Enrollment In Phase 1 Study Of CDX-1140 In Patients With Advanced Solid Tumors
11/17/2017 8:02:43 AM Celldex Initiates Phase 2 Combination Study Of CDX-3379 And Cetuximab In Head And Neck Squamous Cell Carcinoma
11/7/2017 8:05:15 AM Celldex Therapeutics Q3 Net Loss $26.4 Mn Or $0.20 Per Share
9/12/2017 4:02:12 PM Celldex Therapeutics Announces Resignation Of Thomas Davis As EVP And Chief Medical Officer
8/23/2017 9:16:40 AM Celldex Completes Enrollment In Phase 2b Study Of Glembatumumab Vedotin In Triple Negative Breast Cancer